FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of <u>tra Parth</u>	Reporting Person*						e <b>and</b> Tic alth Gr			Symbol PRVA			telationship eck all appli Directo	cable) or	ig Pers	10% Ov	vner	
(Last) PRIVIA	`	irst) GROUP, INC.	(Middle)			Date 6 7/01/2		iest Trans	saction (	Month	h/Day/Year)			Officer (give title below)  Presiden		Other (s below)			
950 N. GLEBE RD., SUITE 700					_ 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(Street) ARLING	GTON V	A	22203										Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		R	Rule 10b5-1(c) Transaction Indication  X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												d to	
		Tak	ole I - N	on-Deri	vativ	e Se	curi	ties Ac	quirec	l, Di	sposed o	f, or Be	neficial	y Owned	l				
			2. Transa Date (Month/D	Execution Year) if any				Transaction Dispose Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and 5		Benefic Owned	es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)	s) 4)		(Instr. 4)	
Common Stock, \$0.01 par value per share			05/01/	05/01/2023				М		20,786	A	\$2	118	3,177		D			
Common Stock, \$0.01 par value per share		05/01/	05/01/2023				S		20,786(1	) <b>D</b>	\$28.03	(2) 97	7,391		D				
Common Stock, \$0.01 par value per share			05/01/	1/2023				S		7,537(3)	D	\$27.58	(4) 89	89,854		D			
Common Stock, \$0.01 par value per share 0			05/02/	/2023	2023		S		7,625(5)	D	\$27.26	5 <sup>(6)</sup> 82,229			D				
		•	Table II								posed of, converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securii (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Purchase)	\$2	05/01/2023			M			11,699	(7)		09/07/2035	Common Stock	11,699	\$0	34,73	9	D		
Stock Option	\$2	05/01/2023			M			9,087	(7)		12/04/2034	Common	9.087	\$0	188,56	52	D		

## **Explanation of Responses:**

(Right to

- 1. The sale of 20,786 shares reported in this row were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2022.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$28.00 to \$28.16 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 3. The sale of 7,537 shares reported in this row represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to a "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold as part of a trade on behalf of multiple employees of Privia Health Group, Inc. in multiple transactions at prices ranging from \$27.29 to \$27.92 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 5. The sale of 7,625 shares reported in this row represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to a "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- 6. The price reported in Column 4 is a weighted average price. The shares were sold as part of a trade on behalf of multiple employees of Privia Health Group, Inc. in multiple transactions at prices ranging from \$26.95 to \$27.87 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 7. All stock options are fully vested and exercisable

## Remarks:

/s/ Thomas Bartrum, as attorney-in-fact

Stock

05/03/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.